Cortical blindness as a manifestation of hypomagnesemia secondary to cisplatin therapy: Case report and review of literature

Gynecologic Oncology

Volumn 72, Issue 1, 1999, Pages 120-122

  Al Tweigeri, Taher ^a,c   Magliocco, Anthony M ^b   DeCoteau, John F ^b  

^a Saskatoon Cancer Center   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Cisplatin; Cortical blindness; Hypomagnesemia; Ophthalmologic toxicity

Indexed keywords

CISPLATIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CEREBRAL BLINDNESS; DRUG EFFECT; FEMALE; HUMAN; HYPOMAGNESEMIA; MAGNESIUM BLOOD LEVEL; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA;

EID: 0032925920     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5211     Document Type: Article

References (35)

1. Feun LG, Stewart DJ, Maor M, et al.: A pilot study of cisplatin and radiation therapy in patients with high grade astrocytomas. J Neuro-Oncol 1:109-113, 1983
2. Granowetter L, Rosenstock JC, Packer RJ: Enhanced cisplatin neurotoxicity in pediatric patients with brain tumors. J Neuro-Oncol 1:293-297, 1983
3. Schaefer SD, Post JD, Close LG, Wright CG: Ototoxicity of low and moderate dose cisplatin. Cancer 56:1934-1939, 1985
4. Roelofs RI, Hrushesky W, Rogin J, Rosenberg L: Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 34:934-938, 1984
5. Thompson SW, Davis LE, Kornfeld M, et al.: Cisplatin neuropathy. Clinical electrophysiologic, morphologic, and toxicologic studies. Cancer 54:1269-1275, 1984
6. Mollman JE, Hogan WM, Glover DJ, Mc-Cluskey LE: Unusual presentation of cisplatin neuropathy. Neurology 38:488-490, 1988
7. Mollman JE, Glover DJ, Hogan WM, Furman RE: Cisplatin nuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 61:2192-2195, 1988
8. Mollman JE: Cisplatin neurotoxicity. N Engl J Med 322:126-127, 1990
9. Gerritsen van der Hop R, Vecht CJ, van der Burg MEL, et al.: Prevention of cisplatin neurotoxicity with an ACTH (4-9) analogue in patients with ovarian cancer. N Engl J Med 322:89-94, 1990
10. Ozols R, Ostecheg Y, Myers C, et al.: High dose of cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 3:1246-1250, 1985
11. Walker RW, Cairncross JG, Posner JB: Cerebral herniation in patients receiving cisplatin. J Neuro-Oncol 6:61-65, 1988
12. Maheley MS, Hipp SW, Dropcho EJ, et al.: Intra-carotid cisplatin chemotherapy for recurrent gliomas. J Neurosurg 70:371-378, 1989
13. Newton HB, Page MA, Junck L, Greenberg HS: Intra-arterial cisplatin for the treatment of malignant gliomas. J Neuro-Oncol 7:39-45, 1989
14. Maiese K, Victor JD, Walker RW, Gargan R: Detection of optic and otictoxicity during intra-arterial cisplatin therapy. Neurology 40(suppl 1):1030S, 1990 (abstract)
15. Kobayashi H, Ohashi N, Watanabe Y, Mizukashi K: Clinical features of cisplatin vestibulotoxicity and hearing loss. ORL J Otorhinolaryngol Relat Spec 49:67-72, 1987
16. Schweitzer VG, Dolan DF, Abram GE, Davidson T, Synder R: Amelioration of cisplatin induced ototoxicity by fosfomycin. Larngoscope 96: 948-958, 1986
17. Boheim K, Bichler E: Cisplatin induced ototoxicity: audiometric finding and experimental cochlear pathology. Arch Otorhinolaryngol 242:1-6, 1985
18. Ostrow S, Hahn D, Wiernik PH, Richards RD: Ophthalmologic toxicity after cisplatin therapy. Cancer Treat Rep 62:1591-1593, 1978
19. Becher R, Schutt P, Osieka R, Schmidt CG: Peripheral neuropathy and ophthalmologic toxicity after cisplatin therapy. J Cancer Res Clin Oncol 96:219-221, 1980
20. Bosl GJ, Lage PH, Fraley EE, et al.: Vinblastine, bleomycin and cisplatin in the treatment of advanced testicular carcinoma. Am J Med 68:492-496, 1980
21. Berman I, Mann M: Seizures and transient cortical blindness associated with cisplatin therapy in a 30-year-old man. Cancer 45:764-766, 1980
22. Pippitt CH, Muss HB, Homesley HD, Jobson VW: Cisplatin associated cortical blindness. Gynecol Oncol 12:253-255, 1981
23. Van Gelder T, Geurs PH, Kho GS, Dippel DWJ, Vecht ChJ: Cortical blindness and seizures following cisplatin treatment both of epileptic origin. Eur J Cancer 29A(10):1497-1498, 1993
24. Cohen RJ, Cuneo RA, Cruciger MP, Jackman AE: Transient left homonymous hemianopsia and encephalopathy following treatment of testicular cancer with cisplatin, vinblastin, and bleomycin. J Clin Oncol 1:392-393, 1983
25. Wilding G, Caruso R, Lawrence TS et al.: Retinal toxicity after high dose cisplatin therapy. J Clin Oncol 3:1683-1689, 1985
26. Miller DF, Bay JW, Lederman RJ, et al.: Ocular and orbital toxicity following intra-carotid injection of BCNU and cisplatin for malignant gliomas. Ophthalmology 92:402-406, 1985
27. Schilsky RL, Anderson T: Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 90:929-931, 1979
28. Lyman NW, Hemalatha C, Viscuso RL: Cisplatin-induced hypocalcemia and hypomagnesemia. Arch Intern Med 140:1513-1514, 1980
29. Aldrich MS, Alessi AG, Beck RW, et al.: Cortical blindness: Etiology, diagnosis and prognosis. Ann Neurol 21:149-158, 1987
30. Adams RD, Victor M: Principles of Neurology. New York, McGraw Hill, 1981, p 313
31. O'Brien MER, Tonge K, Blake P, Moskovic E, Wiltshaw E: Blindness associated with high dose carboplatin. Lancet 339:558, 1992
32. Byrd RL, Rohrbaugh TM, Raney RB, Norris DS: Transient cortical blindness secondary to vincristine therapy in childhood malignancies. Cancer 47:37, 1981
33. Merimsky O, Nisipeanu P, Loewenstein A, Reider-Groswasser I, Chaitchik S. Interferon related cortical blindness. Cancer Chemother Pharmacol 29:329-330, 1992
34. Rubin Am, Kang H: Cerebral blindness and encephalopathy with cyclosporin A toxicity. Neurology 37:1072-1076, 1987
35. Vinken PJ, Bruyn GW, Klawans HL: Hand Book of Clinical Neurology, Amsterdam, Elsevier, 1993, Vol 63, pp 562-563